nach oben

Drugs

Erschienen in:

01.10.2003 | Adis Drug Profile

Tadalafil

verfasst von: Monique P. Curran, Gillian M. Keating

Erschienen in: Drugs | Ausgabe 20/2003

Einloggen, um Zugang zu erhalten

Abstract

▴ Tadalafil is a selective phosphodiesterase type 5 inhibitor that is effective in men with mild-to-severe erectile dysfunction (ED), including those with diabetes mellitus.
▴ The improvement in the erectile function domain score on the International Index of Erectile Function (IIEF) and the percentage of sexual intercourse attempts marked by successful vaginal penetration and completion was significantly greater with on-demand (not more than once daily) tadalafil 10 or 20mg than placebo in trials of 12 weeks’ duration. Improvement in scores on other domains of the IIEF and the percentage of positive responses to a Global Assessment Question measuring erection improvement were also significantly greater with on-demand tadalafil than placebo.
▴ The adverse events associated with tadalafil were generally mild to moderate and decreased in frequency with continued administration. The most commonly reported adverse events were headache and dyspepsia. The incidence of cardiovascular adverse events was not significantly different in tadalafil or placebo recipients.

Use of tradenames is for product identification purposes only and does not imply endorsement.

NIH Consensus Development Panel on Impotence. Impotence. JAMA 1993 Jul 7; 270: 83–90CrossRef

Feldman HA, Goldstein I, Hatzichristou DG, et al. Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study. J Urol 1994 Jan; 151(1): 54–61PubMed

Marumo K, Nakashima J, Murai M. Age-related prevalence of erectile dysfunction in Japan: assessment by the International Index of Erectile Function. Int J Urol 2001 Feb; 8(2): 53–9PubMedCrossRef

Blanker MH, Bosch JL, Groeneveld FP, et al. Erectile and ejaculatory dysfunction in a community-based sample of men 50 to 78 years old: prevalence, concern, and relation to sexual activity. Urology 2001 Apr; 57(4): 763–8PubMedCrossRef

Langtry HD, Markham A. Sildenafil; a review of its use in erectile dysfunction. Drugs 1999; 57: 967–87PubMedCrossRef

Eardley I. New oral therapies for the treatment of erectile dysfunction. Br J Urol 1998 Jan; 81: 122–7PubMedCrossRef

Truss MC, Stief CG. Phosphodiesterase inhibitors in the treatment of erectile dysfunction. Drugs Today 1998 Sep; 34: 805–12PubMed

Rotella DP. Phosphodiesterase type 5 inhibitors: discovery and therapeutic utility. Drugs Future 2001; 26(2): 153–62CrossRef

Angulo J, Gadau M, Fernandez A, et al. IC351 enhances nitric oxide-mediated relaxation of human arterial and trabecular penile smooth muscle [abstract no. 1133 plus poster]. Diabetologia 2001; 44 Suppl. 1: A295

10.

Gbekor E, Bethell S, Fawcett L, et al. Phosphodiesterase 5 inhibitor profiles against all human phosphodiesterase families: implications for use as pharmacological tools [abstract no. 967]. J Urol 2002; 167 Suppl. 4: 246

11.

Meuleman E, Lycklama NGL, Slob K, et al. Effects of IC351 on erectile response to visual sexual stimulation. J Urol 1999 Apr; 161 Suppl.: 212CrossRef

12.

Lilly ICOS Limited. Tadalafil (Cialis™): summary of product characteristics. London: Lilly ICOS Limited, 2003

13.

Porst H, Padma-Natham H, Giuliano F, et al. Efficacy of tadalafil for the treatment of erectile dysfunction at 24 and 36 hours after dosing: a randomised controlled study. Urology 2003; 62: 121–6PubMedCrossRef

14.

Brock GB, McMahon CG, Chen KK, et al. Efficacy and safety of tadalafil in men with erectile dysfunction: results of integrated analysis. J Urol 2002; 168: 1332–6PubMedCrossRef

15.

Padma-Nathan H, Rosen RC, Shabsigh R, et al. Cialis™ (IC351) provides prompt response and extended period of responsiveness for the treatment of men with erectile dysfunction. J Urol 2001 May; 165 Suppl.: 224CrossRef

16.

Hutter Jr AM, Kloner RA, Watkins VS, et al. Blood pressure and cardiovascular effects of tadalafil, a new PDE5 inhibitor [abstract no. P-302 plus poster]. Am J Hypertens 2002; 15 (Pt 2): 140CrossRef

17.

Patterson D, MacDonald TM, Effron MB, et al. Tadalafil does not affect time to ischemia during exercise stress testing in patients with coronary artery disease [abstract no. 1650]. Circulation 2002; 106 (19 Suppl. II): 330

18.

Mitchell M, Sanderson B, Payne C, et al. Pharmacodynamic interaction between alcohol and tadalafil in healthy volunteers [abstract no. P-112]. Proceedings of the 5th Congress of the European Society for Sexual and Impotence Research; 2002 Dec 1-4; Hamburg

19.

Kloner RA, Mitchell MI, Bedding A, et al. Pharmacodynamic interactions between tadalafil and nitrates compared with sildenafil [abstract no. 708]. J Urol 2002; 167 Suppl.: 176

20.

Kloner R, Emmick J, Bedding A, et al. Pharmacodynamic interactions between tadalafil and nitrates [abstract no. 1051-30]. J Am Coll Cardiol 2002; 39 Suppl. A: 291ACrossRef

21.

Patterson B, Bedding A, Jewell H, et al. Dose-normalised pharmacokinetics of tadalafil administered as a single dose to healthy volunteers [abstract no. 600]. Eur Urol 2002; 41 Suppl. 1: 152CrossRef

22.

Porst H. IC351 (tadalafil, Cialis): update on clinical experience. Int J Impot Res 2002 Feb; 14 Suppl. 1: S57–64PubMedCrossRef

23.

Patterson B, Bedding A, Jewell H, et al. The effect of intrinsic and extrinsic factors on the pharmacokinetic properties of tadalafil (IC351) [abstract plus poster]. Proceedings of the 4th Congress of the European Society for Sexual and Impotence Research; 2001 Sep 30–Oct 3; Rome

24.

Sáenz de Tejada I, Anglin G, Knight JR, et al. Effects of tadalafil on erectile dysfunction in men with diabetes. Diabetes Care 2002; 25(12): 2159–64CrossRef

25.

Padma-Nathan H, McMurray JG, Pullman WE, et al. On-demand IC351 (Cialis™) enhances erectile function in patients with erectile dysfunction. Int J Impot Res 2001 Feb; 13(1): 2–9PubMedCrossRef

26.

Anglin G, Iglesias J, Toulouse K, et al. Efficacy and safety of IC351 treatment for erectile dysfunction [abstract no. B8]. Int J Impot Res 2000; 12 Suppl. 3: S75

27.

Rosen RC, Riley A, Wagner G, et al. The international index of erectile function (IIEF): a multidimensional scale for assessment of erectile dysfunction. Urology 1997; 49(6): 822–30PubMedCrossRef

28.

Nash DT. The safety and efficacy of tadalafil in elderly men with ED [abstract no. 48]. Am J Geriatr Cardiol 2003; 12(2): 138–9

29.

Montorsi F, Verheyden B, Junemann K-P, et al. Long-term safety experience with tadalafil [abstract no. 947]. J Urol 2003; 169 Suppl. 4: 245

30.

Kloner RA, Watkins VS, Costigan TM, et al. Cardiovascular profile of tadalafil, a new PDE5 inhibitor [abstract no. 707]. J Urol 2002; 167 Suppl.: 176

31.

Hellstrom W, Overstreet JW, Yu A, et al. Tadalafil has no effect on spermatogenesis or reproductive hormones [abstract no. 948]. 2003; 169 (4 Suppl.): 245

Titel: Tadalafil
verfasst von: Monique P. Curran
Gillian M. Keating
Publikationsdatum: 01.10.2003
Verlag: Springer International Publishing
Erschienen in: Drugs / Ausgabe 20/2003
Print ISSN: 0012-6667
Elektronische ISSN: 1179-1950
DOI: https://doi.org/10.2165/00003495-200363200-00004

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Tadalafil

Abstract

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 20/2003

Caspofungin

Tadalafil

Dual ACE and Neutral Endopeptidase Inhibitors

Adefovir Dipivoxil

Appropriate Empirical Antibacterial Therapy for Nosocomial Infections

Tadalafil